Literature DB >> 27542852

Biological relevance of tissue factor and IL-6 in arteriovenous malformations.

Shouhei Noshiro1,2, Takeshi Mikami3,4, Yuko Kataoka-Sasaki2, Masanori Sasaki2,5,6, Kazuo Hashi2, Shunya Ohtaki1,2, Masahiko Wanibuchi1,2, Nobuhiro Mikuni1, Jeffery D Kocsis5,6, Osamu Honmou2,5,6.   

Abstract

Arteriovenous malformations (AVMs) are congenital abnormal vessels that shunt blood directly from the arterial to the venous system without a capillary bed. The underlying pathology of AVMs is not fully understood. The objective of the study was to determine the association between the expression patterns of tissue factor (TF) and interleukin-6 (IL-6) in AVMs with clinical and pathological findings. Eighteen cases of sporadic AVM with operative specimens were included in this study. The expression of messenger RNA (mRNA) of TF and IL-6 was assayed, and association with clinical factors was investigated. The distribution of TF and IL-6 was examined with immunofluorescence. The mRNA expression of TF was significantly higher in AVM specimens than in control tissues (P = 0.002) and significantly higher in the symptomatic group than in the asymptomatic group (P = 0.037). The mRNA expression of IL-6 was likewise significantly higher in AVM specimens than in control tissues (P = 0.038). Examination of immunostained sections indicated that TF+ cells were also positive for IL-6 and were distributed around normal endothelial cells and pericytes. Moreover, TF+/IL-6+ cells also expressed CD31, vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta (PDGFR-beta). These results suggest that TF is elevated in AVMs and that it mediates symptomatic events. IL-6 is associated with the angiogenic activity of TF, and both are present in the same abnormal endothelial cells and pericytes. These factors may have interactive effects and may serve in a prognostic role for AVMs.

Entities:  

Keywords:  Cerebral arteriovenous malformations; Endothelial cell; Interleukin-6; Tissue factor

Mesh:

Substances:

Year:  2016        PMID: 27542852     DOI: 10.1007/s10143-016-0780-1

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  45 in total

Review 1.  Endothelial precursor cell migration during vasculogenesis.

Authors:  Annette Schmidt; Klara Brixius; Wilhelm Bloch
Journal:  Circ Res       Date:  2007-07-20       Impact factor: 17.367

2.  Role of tissue factor in embryonic blood vessel development.

Authors:  P Carmeliet; N Mackman; L Moons; T Luther; P Gressens; I Van Vlaenderen; H Demunck; M Kasper; G Breier; P Evrard; M Müller; W Risau; T Edgington; D Collen
Journal:  Nature       Date:  1996-09-05       Impact factor: 49.962

3.  Interleukin-6 involvement in brain arteriovenous malformations.

Authors:  Yongmei Chen; Ludmila Pawlikowska; Jianhua S Yao; Fanxia Shen; Wenwu Zhai; Achal S Achrol; Michael T Lawton; Pui-Yan Kwok; Guo-Yuan Yang; William L Young
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

Review 4.  Initiation of coagulation by tissue factor.

Authors:  R R Bach
Journal:  CRC Crit Rev Biochem       Date:  1988

5.  Outcome after conservative management or intervention for unruptured brain arteriovenous malformations.

Authors:  Rustam Al-Shahi Salman; Philip M White; Carl E Counsell; Johann du Plessis; Janneke van Beijnum; Colin B Josephson; Tim Wilkinson; Catherine J Wedderburn; Zoe Chandy; E Jerome St George; Robin J Sellar; Charles P Warlow
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

6.  Multiple dynamic cavernous malformations in a girl: long-term follow-up.

Authors:  Liang Chen; Yao Zhao; Zheng Chen; May Tee; Ying Mao; Liang-Fu Zhou
Journal:  Surg Neurol       Date:  2009-07-14

Review 7.  Specificity of coagulation factor signaling.

Authors:  W Ruf; A Dorfleutner; M Riewald
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

Review 8.  The diagnosis and management of brain arteriovenous malformations.

Authors:  Roberta L Novakovic; Marc A Lazzaro; Alicia C Castonguay; Osama O Zaidat
Journal:  Neurol Clin       Date:  2013-04-17       Impact factor: 3.806

9.  Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells.

Authors:  Hongyu Tian; Karthikeyan Mythreye; Christelle Golzio; Nicholas Katsanis; Gerard C Blobe
Journal:  EMBO J       Date:  2012-08-31       Impact factor: 11.598

10.  Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.

Authors:  J P Mohr; Michael K Parides; Christian Stapf; Ellen Moquete; Claudia S Moy; Jessica R Overbey; Rustam Al-Shahi Salman; Eric Vicaut; William L Young; Emmanuel Houdart; Charlotte Cordonnier; Marco A Stefani; Andreas Hartmann; Rüdiger von Kummer; Alessandra Biondi; Joachim Berkefeld; Catharina J M Klijn; Kirsty Harkness; Richard Libman; Xavier Barreau; Alan J Moskowitz
Journal:  Lancet       Date:  2013-11-20       Impact factor: 79.321

View more
  1 in total

1.  Germline Mutation Enrichment in Pathways Controlling Endothelial Cell Homeostasis in Patients with Brain Arteriovenous Malformation: Implication for Molecular Diagnosis.

Authors:  Concetta Scimone; Francesca Granata; Marcello Longo; Enricomaria Mormina; Cristina Turiaco; Antonio A Caragliano; Luigi Donato; Antonina Sidoti; Rosalia D'Angelo
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.